(Q44127740)

English

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial (English)

1 reference

Europe PubMed Central

30 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maximilian von Eynatten

4

object named as

M von Eynatten

1 reference

Europe PubMed Central

30 November 2017

author name string

B Gallwitz

1

1 reference

Europe PubMed Central

30 November 2017

J Rosenstock

2

1 reference

Europe PubMed Central

30 November 2017

S Patel

3

1 reference

Europe PubMed Central

30 November 2017

U Hehnke

5

1 reference

Europe PubMed Central

30 November 2017

L Mehlburger

6

1 reference

Europe PubMed Central

30 November 2017

K A Dugi

7

1 reference

Europe PubMed Central

30 November 2017

H-J Woerle

8

1 reference

Europe PubMed Central

30 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 January 2015

1 reference

Europe PubMed Central

30 November 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

30 November 2017

17

1 reference

Europe PubMed Central

30 November 2017

3

1 reference

Europe PubMed Central

30 November 2017

276-284

1 reference

Europe PubMed Central

30 November 2017

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010: a German longitudinal population-based study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Emergency hospitalizations for adverse drug events in older Americans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Drug-induced hypoglycaemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12419

21 January 2018

Identifiers

10.1111/DOM.12419

1 reference

Europe PubMed Central

30 November 2017

release_5ijlarbj5jgoditw5baze7pxma

1 reference

https://api.fatcat.wiki/v0/release/5ijlarbj5jgoditw5baze7pxma

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44127740&oldid=2106876133"